Plus   Neg

Clovis Oncology Inc. (CLVS) Is Pulling Back After Stock Offering

Clovis Oncology Inc. (CLVS) announced after the bell Monday that it has commenced an underwritten public offering of its common stock in an effort to raise approximately $250 million. The stock is now down 1.13 on 179K shares.

Clovis Oncology gapped open dramatically higher Monday after it announced that its Phase 3 trial of rucaparib successfully achieved the primary endpoint of improved progression-free survival in patients with ovarian cancer. Shares finished with a gain of 27.91 at $87.88 with volume at an 8-month high. The stock soared to a new high for the year.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT